Loading
TG4050 is an experimental individualised neoantigen therapeutic vaccine from Transgene, in phase 2 trials for HPV-negative head and neck squamous cell carcinoma and ovarian cancer.
TG4050 is an individualised neoantigen therapeutic vaccine (myvac platform) from Transgene. The lead individualised neoantigen therapeutic vaccine from Transgene's myvac platform, given as a single agent after surgery. Its furthest stage is phase 2, for HPV-negative head and neck squamous cell carcinoma (adjuvant) and ovarian cancer. ClinicalTrials.gov registers it in 2 studies linked below. Transgene: randomised multicentre phase 2 part of a phase 1/2 trial (NCT04183166, active, not recruiting). An ovarian cancer phase 1 (NCT03839524) is completed. Whether it works in people has not been established unless a trial below reports it.
The lead individualised neoantigen therapeutic vaccine from Transgene's myvac platform, given as a single agent after surgery.
1.TG4050 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TG4050" OR ABSTRACT:"TG4050") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TG4050, not a curated reading list.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer) and the tag pipeline.
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer) and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/